Endoscopic atrophic classification before and after H. pylori eradication is closely associated with histological atrophy and intestinal metaplasia

Background and study aims: The relationship between endoscopic atrophy classification (EAC) and histological gastric atrophy and intestinal metaplasia (IM) was examined before and after Helicobacter pylori (H. pylori) eradication in order to evaluate the usefulness of EAC for detecting the risk of gastric cancer following eradication.

Patients and methods: A total of 230 patients (137 males, 93 females; mean age: 58.0±11.8 y) with successful eradication were enrolled. EAC score was defined as follows: C0(none): 0, C1: 1, C2: 2, C3: 3, O1: 4, O2: 5, and O3(severe): 6. Histological atrophy and IM score (0 to 3) from the antrum and the corpus were evaluated with updated Sydney system for histological atrophy and IM.

Results: The mean EAC scores were 3.46 before eradication and 3.20 after eradication (P=0.026). The mean atrophy scores before and after eradication were 1.45 and 0.92 at the antrum (P<0.001) and 0.50 and 0.07 at the corpus (P<0.001), respectively. The mean IM scores before and after eradication were 0.55 and 0.47 at the antrum (P=0.154), and 0.09 and 0.05 at the corpus (P=0.096), respectively. The histological atrophy scores showed significant improvement after eradication, while IM showed no significant change. The Mantel-Haenszel test for trend indicated there was a significant correlation between EAC and histological atrophy and IM, except antral atrophy after eradication.

Conclusions: EAC exhibited a significant correlation between histological atrophy and IM, and represents a noninvasive classification method. EAC may be beneficial in evaluating the risk of gastric cancer after H. pylori eradication.

Introduction

Helicobacter pylori (H. pylori) infection has been recognized as a major pathogen of gastric cancer [1,2]. Correspondingly, several reports have indicated that H. pylori eradication therapy mediates a preventive effect against gastric cancer development [3–6]. However, gastric cancer was still found to persist in some cases. Therefore, a more simple and straightforward observation method is necessary to monitor gastric cancer following H. pylori eradication.

Histological gastric atrophy and intestinal metaplasia (IM) are regarded as precancerous lesions, and are recognized as risk factors both before and after H. pylori eradication [2,7]. Endoscopic atrophy classification (EAC) according to Kimura and Takemoto [8] has frequently been used to evaluate the atrophic degree of gastric mucosa. Moreover, the degree of EAC has been found to correlate with the degree of histological atrophy [8,9]. However, these studies do not mention the correlation between EAC and atrophy and IM after eradication. In addition, EAC is associated with the incidence of gastric cancer after eradication [10], and provides a noninvasive method for predicting gastric cancer after eradication compared with biopsy of gastric mucosa [10,11]. While H. pylori eradication has been shown to reduce the degree of gastric atrophy and IM [12–15], the correlation between EAC and post-H. pylori eradicated gastric mucosa and, in particular, atrophy and IM status has not been investigated yet. Therefore, in this study, the relationship between EAC and histological gastric atrophy and IM not only before but also after H. pylori eradication was examined in order to evaluate the usefulness of EAC for detecting the risk of gastric cancer following H. pylori eradication.

Patients and Methods

A total of 325 patients who underwent upper gastrointestinal endoscopy and had examination for detection of H. pylori at Oita University Hospital...
between January 1995 and December 2010 were enrolled in this study. The patients with *H. pylori* infection subsequently underwent *H. pylori* eradication. These subjects were examined repeatedly with endoscopy more than 3 years after *H. pylori* eradication in order to survey gastric mucosal alteration after eradication. All study protocols were approved by an institutional review board. To detect *H. pylori*, patients underwent at least one of the following assays: a rapid urease test (RUT), histology, culture testing, and/or a urea breath test (UBT). A subset of patients underwent all of the assays. Only histology and culture tests were used for *H. pylori* diagnosis until RUT and UBT were developed. After confirming the safety of eradication therapy and obtaining further informed consent, patients with *H. pylori* were administered a proton pump inhibitor-based combination therapy. Briefly, between 4 weeks and 6 months after completing eradication therapy, RUT, histology, cultures, and/or UBT examinations were repeated. *H. pylori* eradication was considered successful if all tests were negative. *H. pylori*-negative cases and cases involving *H. pylori* recrudescence or reinfection were excluded. Endoscopies were also repeated for patients who underwent successful *H. pylori* eradication. The endoscopic findings performed 78.05±36.72 (range 36–153) months after eradication were evaluated for this study.

**Endoscopic evaluation**

The endoscopic examinations were performed using an Olympus endoscope (model Q-240, 260, HQ-260, and others; Tokyo, Japan). Endoscopic atrophy was defined using an endoscopic-atrophic-border scale previously reported by Kimura and Take-moto [8]. This scale correlates with histological results [8, 9] and includes the following classifications: 1) close-type, when the atrophic border remains on the lesser curvature of the stomach; and 2) open-type, when the atrophic border extends along the anterior and posterior walls of the stomach and is not associated with the lesser curvature of the stomach. Close-type and open-type atrophy were further classified as none (C0), mild (C1, 2), moderate (C3, O1), and severe (O2, 3) atrophy (Fig. 1). In this study, atrophy grade were also scored as C0: 0, C1: 1, C2: 2, C3: 3, O1: 4, O2: 5, and O3: 6 respectively, with 0 representing an absence of atrophy and 6 indicating severe atrophy.

**Histological evaluation**

Biopsies were performed prior to eradication in order to diagnose *H. pylori*. Biopsy specimens were obtained from the greater curvature of the antrum and the greater curvature of the corpus, which are two of five points recommended by updated Sydney system [16]. Gastric mucosa samples were subsequently evaluated according to updated Sydney system with the degree of inflammation, neutrophil activity, atrophy, and IM classified as: 0, ‘normal’; 1, ‘mild’; 2, ‘moderate’; and 3, ‘marked’. Grade of histological gastritis was evaluated with this score 0, 1, 2, and 3. Histological evaluations were performed by two experienced pathologists from Oita University Hospital. Correlations between endoscopic atrophy classification scores and histological atrophic scores were evaluated before and after *H. pylori* eradication.

**Statistical analysis**

Statistical analyses were performed using SPSS software (PASW Statistics 18, SPSS Japan), and data are expressed as the mean ± standard deviation. Student’s *t*-test was performed to compare updated Sydney system scores before and after eradication. The Mantel-Haenszel test for trend was used to compare endoscopic atrophic degree, histological gastric atrophy, and IM. *P*-values less than 0.05 were considered significant.

**Results**

**Disease history**

Of 325 subjects, those who were *H. pylori*-negative or had unsuccessful eradication or recurrence of *H. pylori* infection were excluded (Fig. 2). Forty-three cases were lost during observation. A total of 230 patients (137 males, 93 females) were analyzed. The mean age of this cohort at the time of eradication was 58.0±11.8y. The cohort was also characterized by a history of chronic gastritis (n=105), gastric ulcers (n=54), duodenal ulcers (n=45), gastroduodenal ulcers (n=13), gastric cancer (n=7), gastric adenoma (n=1), and mucosal-associated lymphoid tissue lymphoma (n=5).
Endoscopic gastric atrophy
Prior to H. pylori eradication, the endoscopic atrophic grades assigned to the cohort included: C1 (n=22), C2 (n=47), C3 (n=41), O1 (n=61), O2 (n=36), and O3 (n=23). After eradication, endoscopic findings that were performed 78.05 ± 36.72 (range 36–153) months after eradication were evaluated. The results of endoscopic examination at the beginning and the end of the observation period were assessed. The endoscopic grades were C1 (n =20), C2 (n = 58), C3 (n =59), O1 (n =50), O2 (n =31), and O3 (n =12). Compared with the grades assigned before eradication, an improvement in endoscopic grade was observed following successful eradication in 94 cases, while no change or exacerbation of atrophy was observed in 78 cases and 58 cases, respectively. The mean endoscopic gastric atrophy score for all of the cases was 3.46 ±1.43 before eradication and significantly reduced to 3.20 ± 1.33 after eradication (P=0.026).
Atrophy scores, except C1 and O3, showed significant reductions following eradication. At the corpus, the histological atrophy scores before and after eradication for each endoscopic grade were: C1: 0.26 and 0.00 ($P = 0.028$); C2: 0.28 and 0.02 ($P = 0.003$); C3: 0.51 and 0.04 ($P < 0.001$); O1: 0.56 and 0.11 ($P < 0.001$); O2: 0.70 and 0.04 ($P < 0.001$); O3: 0.74 and 0.50 ($P = 0.29$), respectively (● Fig. 5 b). Atrophy scores, except for O3, showed significant reductions following eradication.

The $P$-value for the Mantel-Haenszel test for trend was 0.008 before eradication and 0.069 after eradication at the antrum, and was 0.004 before eradication and 0.031 after eradication at the corpus. The trend in EAC and histological atrophy was significant before eradication and after eradication, except at the antrum after eradication (● Fig. 5 b). Atrophy scores, except for O3, showed significant reductions following eradication.

The $P$-value for the Mantel-Haenszel test for trend was 0.008 before eradication and 0.069 after eradication at the antrum, and was 0.004 before eradication and 0.031 after eradication at the corpus. The trend in EAC and histological atrophy was significant before eradication and after eradication, except at the antrum after eradication (● Fig. 5 b). Atrophy scores, except for O3, showed significant reductions following eradication (● Fig. 5 a, b). At the antrum, the histological IM scores before and after eradication for each endoscopic grade were: C1: 0.21 and 0.21 ($P = 0.50$); C2: 0.31 and 0.26 ($P = 0.35$); C3: 0.72 and 0.47 ($P = 0.11$); O1: 0.56 and 0.59 ($P = 0.43$); O2: 0.73 and 0.69 ($P = 0.45$); O3: 0.90 and 1.10 ($P = 0.32$), respectively (● Fig. 6 a). At the corpus, the histological IM scores before and after eradication for each endoscopic grade were: C1: 0.00 and 0.05 ($P = 0.17$); C2: 0.02 and 0.00 ($P = 0.16$); C3: 0.08 and 0.00 ($P = 0.992$); O1: 0.09 and 0.06 ($P = 0.38$); O2: 0.18 and 0.08 ($P = 0.18$); O3: 0.26 and 0.50 ($P = 0.27$), respectively (● Fig. 6 b). None of the IM scores after eradication for any of EAC levels exhibited any significant improvement at both the antrum and the corpus. The $P$-value for the Mantel-Haenszel test for trend was 0.005 before eradication and <0.0001 after eradication at the antrum, and 0.048 before eradication and 0.027 after eradication at the corpus. EAC and histological IM showed a significant trend both before and after eradication (● Fig. 6 a, b).

**Discussion**

Although *H. pylori* eradication has the potential to prevent gastric cancer, recurrence of gastric cancer has been observed following *H. pylori* eradication [4–6, 17, 18]. Therefore, the incidence of gastric cancer recurrence after *H. pylori* eradication remains to be fully characterized. Although molecular factors predictive of gastric cancer are useful [19, 20], simpler methods are believed to be desirable. Atrophy and IM have been recognized as risk factors for gastric cancer following *H. pylori* eradication [10, 11, 21–23]. Intestinal-type gastric cancer, appears to undergo a multi-step carcinogenic process, from atrophic gastritis to IM to dysplasia [7]. To identify high-risk factors for cases of gastric cancer that develop after *H. pylori* eradication, a minimally invasive method, such as endoscopic findings without biopsy, is needed. In general, annual endoscopy has been reported to be useful in detecting most new tumors, and is associated with improved rates of survival [24]. Therefore, endoscopic surveillance after eradication is considered to be very important. Current results cannot identify the surveillance period that is optimal in each individual case. Further examination is necessary to identify the optimal surveillance period for low-risk and high-risk patients. The use of specific wavelengths of light, such as magnifying narrow-band imaging [25–27] for performing endoscopies has been used recently. Currently, this method is very useful for gastric cancer surveillance. However, we hypothesize that a more basic and cost-effective observation method may help evaluate gastric cancer development following *H. pylori* eradication. In the current study, a significant correlation between EAC and histological atrophy before eradication was identified, and this result is consistent with that of previous reports [8, 9, 28]. However, to our knowledge, this is the first study to identify a correlation between EAC and histological atrophy both before and after *H. pylori* eradication. Patients with...
Fig. 5 Relationship between endoscopic atrophy scores and histological atrophy scores before and after *H. pylori* eradication. Each degree of endoscopic atrophy showed significant improvement of histological atrophy following eradication, except for C1 and O3 at the antrum, and O3 at the corpus. Endoscopic atrophy classification showed significant correlation with histological atrophy except antral site after eradication.

Fig. 6 Relationship between endoscopic atrophy scores and histological IM scores before and after *H. pylori* eradication. Each degree of endoscopic atrophy showed no significant improvement of IM after eradication. Endoscopic atrophy classification showed significant correlation with histological IM at both sites before and after eradication.
severe endoscopic atrophy have a high risk of gastric cancer after eradication [10, 22, 23], and our previous study indicated that patients who develop gastric cancer after eradication exhibit severe endoscopic atrophy and histological antral atrophy compared with patients without gastric cancer [11]. Furthermore, a more severe grade of IM has been observed in gastric cancer cases following eradication [23]. Therefore, it has been hypothesized that EAC is valid to judge gastric cancer risk before \textit{H. pylori} eradication. Although the endoscopic index of successful eradication was evaluated [29], EAC and histological IM have not been compared over a long period of time following eradication. In the current study, EAC and histological atrophy were significantly correlated at the corpus. In addition, almost every degree of endoscopic atrophy that was observed in the current cohort following eradication was accompanied by a significantly low level of histological atrophy compared with levels prior to eradication. These results suggest that there is less improvement in endoscopic atrophy than in histological atrophy following eradication. In \textbf{Fig. 4}, histological atrophy and IM are shown to be improved after eradication, while an improvement in endoscopic atrophy was not observed. Thus, the degree of histological atrophy after eradication was milder than that observed before eradication for a similar endoscopic atrophy range.

There was also no significant relation between EAC and histological atrophy at the antrum following eradication. This result is attributed to the observation that severe histological atrophy was remarkably improved following eradication. However, histological IM exhibited a significant correlation with endoscopic atrophy degree at the antrum both before and after eradication. Therefore, as the degree of endoscopic atrophy becomes more extensive, histological IM at the antrum also becomes more extensive, even after \textit{H. pylori} eradication. Moderate-to-severe endoscopic atrophy has been reported to exhibit extensive incomplete IM [30], which is consistent with the IM distribution observed in the current study. Unlike histological atrophy, no significant difference in the degree of histological IM was observed before and after eradication. Many studies have indicated that the gastric mucosa undergoes alterations following \textit{H. pylori} eradication [12 – 15]. However, in two recent meta-analyses, improvement in atrophic gastritis, but not IM, was observed following \textit{H. pylori} eradication [13, 14]. In our previous study, histological atrophy was found to improve, however, IM only improved at the lesser curvature of the corpus following eradication [15]. In the current study, no significant alterations in IM before and after eradication were observed, consistent with results of these previous studies. Because the long observation period may have influenced the results of this study, further study of cases involving surveillance during a narrower time period may be necessary.

Regarding the strong correlation between EAC and histological IM, it has been suggested that EAC is a useful index for long-term gastric cancer risk following \textit{H. pylori} eradication. In general, IM does not improve following eradication, neither does dysregulation of micro-RNAs in IM [31]. Taken together, these results suggest that IM should be regarded as one of the most informative factors predictive of gastric cancer following \textit{H. pylori} eradication. Furthermore, because gastric cancer tends to develop more frequently at the antrum than at the corpus following \textit{H. pylori} eradication [23], the strong association between EAC and histological IM at the antrum may indicate that EAC may not depend on whether screening for gastric cancer is performed before or after \textit{H. pylori} eradication. In conclusion, EAC exhibited a significant correlation with histological atrophy and IM at the antrum and corpus in the gastric mucosa before and after \textit{H. pylori} eradication, except for antral atrophy after eradication. Thus, EAC may be useful for observations of histological atrophy and IM degree independent of invasive biopsies, and it may also be beneficial for evaluating the risk of gastric cancer after \textit{H. pylori} eradication.

Competing interests: None

References

1. Huang JQ, Sridhar S, Chen Y et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114: 1169 – 1179
2. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784 – 787
3. Fuccio L, Zagari RM, Eusebi LH et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151: 121 – 128; Erratum: in Ann Intern Med 2009; 151: 516
4. Ito M, Takata S, Tatsugami M et al. Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review. J Gastroenterol 2009; 44: 365 – 371
5. Take S, Mizuno M, Ishiki K et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol 2011; 46: 318 – 324
6. Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392 – 397
7. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process–first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 1992; 52: 6735 – 6740
8. Kimura T, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 3: 87 – 97
9. Satoh K, Kimura K, Taniguchi Y et al. Distribution of inflammation and atrophy in the stomach of Helicobacter pylori–positive and –negative patients with chronic gastritis. Am J Gastroenterol 1996; 91: 963 – 969
10. Take S, Mizuno M, Ishiki K et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005; 100: 1037 – 1042
11. Kodama M, Murakami K, Okimoto T et al. Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer. Scand J Gastroenterol 2013; 48: 1249 – 1256
12. Murakami K, Kodama M, Sato R et al. Helicobacter pylori eradication and associated changes in the gastric mucosa. Expert Rev Anti Infect Ther 2005; 3: 757 – 764
13. Rokitas T, Pielola D, Sechopoulos P et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 2007; 12: 32 – 38
14. Wang J, Xu L, Shi R et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011; 83: 253 – 266
15. Kodama M, Murakami K, Okimoto T et al. Ten-year prospective follow-up of histological changes at 5 points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol 2012; 47: 394 – 403
16. Dixon MF, Genta RM, Yardley JH et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1994; 20: 1161 – 1181
17. Bao SE, Jang HY, Kang J et al. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol 2014; 109: 60 – 67
18. Choi J, Kim SG, Yoon H et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol 2014; 12: 793 – 800
19. Wairati J, Moriichi K, Tanabe H et al. Biomarkers predicting development of metachronous gastric cancer after endoscopic resection: an analysis of molecular pathology of Helicobacter pylori eradication. Int J Cancer 2012; 130: 2349 – 2358

Kodama Masaaki et al. Association between endoscopic and histological atrophy of the stomach... Endosc Int Open 2015; 03: E311–E317
Kim HJ, Hwang SW, Kim N et al. Helicobacter pylori and Molecular Markers as Prognostic Indicators for Gastric Cancer in Korea. J Cancer Prev 2014; 19: 56–67

Leung WK, Sung JFY. Intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther 2002; 16: 1209–1216

Kamada T, Hata J, Sugiu K et al. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther 2005; 21: 1121–1126

Tashiro J, Miwa J, Tomita T et al. Gastric cancer detected after Helicobacter pylori eradication. Digestive Endoscopy 2007; 19: 167–173

Whiting JL, Sigurdsson A, Rowlands DC et al. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 2002; 50: 378–381

Nakayoshi T, Tajiri H, Matsuda K et al. Magnifying endoscopy combined with narrow band imaging system for early gastric cancer: correlation of vascular pattern with histopathology (including video). Endoscopy 2004; 36: 1080–1084

Uedo N, Ishihara R, Iishi H et al. A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. Endoscopy 2006; 38: 819–824

Okubo M, Tahara T, Shibata T et al. Usefulness of magnifying narrow-band imaging endoscopy in the Helicobacter pylori-related chronic gastritis. Digestion 2011; 83: 161–166

Liu Y, Uemura N, Xiao SD et al. Agreement between endoscopic and histological gastric atrophy scores. J Gastroenterol 2005; 40: 123–127

Kato M, Terao S, Adachi K et al. Study Group for Establishing Endoscopic Diagnosis of Chronic Gastritis. Changes in endoscopic findings of gastritis after cure of H. pylori infection: multicenter prospective trial. Dig Endosc 2013; 25: 264–273

Quach DT, Le HM, Hiyama T et al. Relationship between endoscopic and histologic gastric atrophy and intestinal metaplasia. Helicobacter 2013; 18: 151–157

Shiotani A, Uedo N, Iishi H et al. H. pylori eradication did not improve dysregulation of specific oncogenic miRNAs in intestinal metaplastic glands. J Gastroenterol 2012; 47: 988–998